about
Understanding cognition in older patients with cancerCancer-treatment-induced neurotoxicity--focus on newer treatmentsProtecting the normal in order to better kill the cancerNew drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Glutathione-degradable drug-loaded nanogel effectively and securely suppresses hepatoma in mouse model.High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study.Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage.Differential role of RIP1 in Smac mimetic-mediated chemosensitization of neuroblastoma cells.Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?Chemotherapy-Related Neurotoxicity.The confused oncologic patient: a rational clinical approach.Dorsal column myelopathy after intrathecal chemotherapy for leukemia.Prospective assessment of white matter integrity in adult stem cell transplant recipientsMethotrexate-induced leukoencephalopathy presenting as stroke in the emergency department.Application of Theranostics in Oncology.Chimeric antigen receptor transduced T cells: Tuning up for the next generation.Immunotherapy with the trifunctional anti-CD20 × anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease.Non-convulsive seizure related to Cremophor EL™-free, polymeric micelle formulation of paclitaxel: a case report.Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis.Disparities in Neurotoxicity Risk and Outcomes among Pediatric Acute Lymphoblastic Leukemia PatientsJacalin-capped silver nanoparticles minimize the dosage use of the anticancer drug, shikonin derivatives, against human chronic myeloid leukemia
P2860
Q26747296-DDA0A255-C7FC-4024-929B-6CFDCB76FC10Q26782604-B0497D22-37D6-4B91-9C45-A47CE6486F21Q26801291-8CAF824B-A556-4F73-A088-CB59271A4A2EQ33564645-E440FECA-87EB-44F9-A6B1-6873B259077AQ35223221-63025F7E-A2C1-4024-B921-5ABD7381A807Q36212932-DEA369C1-BAC7-4D52-9328-C8146ED284FEQ37020999-C2B85274-26AE-4880-A868-BFFF4C663253Q37655675-8E8CE580-3ECE-4B91-9042-E06E274847C9Q38310891-95AC01C7-6EA4-407B-B52C-9904081D2EB7Q38673114-8C543299-EABB-4E92-B172-B13F49298238Q38701140-5E24DF9D-F570-4594-9A41-595B96328513Q38904676-ABBA0882-A894-4B59-B235-3E3B16D1225EQ38965811-D681964F-6D2A-43F9-8524-1DC3EE026418Q39164378-FF03F365-A511-4B04-9169-85897EF752F3Q41604163-8F40CB4C-61CB-489B-B652-40F9AE9A6C4CQ42220380-610A45C2-E26B-437B-811D-4418147CEDC9Q42516119-501C210C-C824-4F6A-A691-EB96FD693A5CQ48337005-324E7BD8-2A48-4D96-BFAF-8824AA095483Q52842514-45FC6158-5A33-4D9F-8146-49A19F898631Q55031659-FF82D31B-6CB9-4AAF-8C1F-C03951736E92Q55384404-F7292BCF-FC04-4F90-AC8C-D93D36E2975CQ57462209-40ECA784-2AF7-42D8-AA04-0A266C807119Q58022800-351FABE8-69EE-4E1F-9E35-55831648A3F3
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The double-edged sword: Neurotoxicity of chemotherapy.
@en
type
label
The double-edged sword: Neurotoxicity of chemotherapy.
@en
prefLabel
The double-edged sword: Neurotoxicity of chemotherapy.
@en
P2860
P1433
P1476
The double-edged sword: Neurotoxicity of chemotherapy.
@en
P2093
Rajiv S Magge
P2860
P304
P356
10.1016/J.BLRE.2014.09.012
P577
2014-09-28T00:00:00Z